Xlife Sciences AG: Successful First Half of 2024 with Strategic Progress and Solid Financial Figures

Xlife Sciences AG (SIX: XLS) reported strong results for the first half of 2024, highlighting significant advancements in business development and financial performance. The Zurich-based company has expanded its innovative portfolio and established new partnerships, despite a challenging market environment.

The company’s diversified portfolio includes 25 project companies with notable achievements. x-nuclear diagnostics GmbH introduced the promising PET-tracer DAZAmed for liver diagnostics. VERAXA Biotech AG secured an exclusive license in hemibody technology, while novaxomx GmbH made significant strides towards market readiness with its bone growth promotion tests. FUSE-AI GmbH successfully launched its AI software for prostate cancer diagnosis, and palleos healthcare GmbH strengthened its position through a strategic merger.

Financially, Xlife Sciences generated revenue of CHF 349,818, with earnings per share rising to CHF 0.08. The balance sheet total increased to CHF 509.9 million, and equity reached CHF 367.0 million.

Internationally, the company expanded its partnerships in Abu Dhabi, collaborating with Thermo Fisher Scientific and Masdar City, reinforcing its global presence in life sciences and clinical research.